Young Kwang Chae, Professor and Co-Director of Developmental Therapeutics, Lurie Cancer Center at Northwestern University, shared a post on X:
“ADC revolution is marching on!
At AACR26 plenary, Raffaele Colombo, Zymeworks Inc., discussed new breakthroughs in RAS inhibition
Pan-RASi RMC-6236 shows real benefit (38% ORR in NSCLC, 25% in PDAC), but skin/GI toxicity dose reductions remain a major problem
Solution? RASi-ADCs – same target, sustained tumor delivery, far less systemic exposure 170+ novel payloads screened – DAR=8 ADCs show strong efficacy at 1mg/kg, good PK, bystander killing, and no skin or GI tox in NHPs
Key data: RASi-ADCs suppress RAS in the tumor – but spare liver, skin colon. RMC-6236 doesn’t.
The future of RAS therapy may be in the syringe, rather than the pill.”
Other articles featuring Young Kwang Chae and Raffaele Colombo on OncoDaily.
